Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. Robert C, Long GV, Brady B, Dutriaux C, et al. J Clin Oncol 2020 Sep 30:JCO2000995. doi: 10.1200/JCO.20.00995.

Read + Share

Amedeo Smart

Independent Medical Education

Robert C, Long GV, Brady B, Dutriaux C, et al. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. J Clin Oncol 2020 Sep 30:JCO2000995. doi: 10.1200/JCO.20.00995.
PMID: 32997575